{"created":"2023-06-20T16:49:50.335337+00:00","id":22142,"links":{},"metadata":{"_buckets":{"deposit":"88738e37-4ae7-46ba-9d4a-8d8073633def"},"_deposit":{"created_by":3,"id":"22142","owners":[3],"pid":{"revision_id":0,"type":"depid","value":"22142"},"status":"published"},"_oai":{"id":"oai:kindai.repo.nii.ac.jp:00022142","sets":["14:2667:4710"]},"author_link":["43370"],"control_number":"22142","item_8_biblio_info_21":{"attribute_name":"書誌情報","attribute_value_mlt":[{"bibliographicIssueDates":{"bibliographicIssueDate":"2021","bibliographicIssueDateType":"Issued"},"bibliographicPageEnd":"7","bibliographicPageStart":"1","bibliographic_titles":[{"bibliographic_title":"科学研究費助成事業研究成果報告書 (2020)"}]}]},"item_8_description_25":{"attribute_name":"リンクURL","attribute_value_mlt":[{"subitem_description":"https://kaken.nii.ac.jp/grant/KAKENHI-PROJECT-19K16876/","subitem_description_type":"Other"}]},"item_8_description_33":{"attribute_name":"抄録","attribute_value_mlt":[{"subitem_description":"研究成果の概要（和文）：本研究では、申請者らが独自に取得したグルタミントランスポーターASCT2を認識するモノクローナル抗体による、抗がん効果について検討した。本抗体の処置により、KRAS遺伝子が変異したヒト大腸癌細胞のグルタミン取込みが有意に減少した。さらに、これらの細胞由来の腫瘍の増殖も有意に低下した。しかしながら、KRAS遺伝子が変異していない大腸癌細胞では、本抗体の処置によるグルタミン取込みおよび腫瘍増殖に変化は認められなかった。以上の結果より、KRAS遺伝子が変異した大腸癌において、ASCT2は有用な治療標的である可能性が考えられる。研究成果の概要（英文）：Mutations in KRAS are detected in various human cancers. However, there are few effective drugs for KRAS-mutated cancers. Glutamine is thought to be one of the pivotal nutrients for proliferation and survival of cancer cells. ASCT2 (SLC1A5) is a multi-pass  transmembrane protein that transports neutral amino acids. ASCT2 is reported to be highly expressed in many cancer cells, and is thought to work as a major transporter for glutamine. We have developed a novel monoclonal antibody (mAb) against the extracellular domain of human ASCT2. In the present study, we examined the effects of the mAb on KRAS-mutated colorectal cancer cells. Treatment with anti-ASCT2 mAb decreased the concentration of intracellular glutamine and in vivo tumor growth. However, these effects were not observed in colorectal cancer cells which harbor wild-type KRAS. These results suggest that ASCT2 is a promising therapeutic target for KRAS-mutated cancers.","subitem_description_type":"Abstract"}]},"item_8_description_36":{"attribute_name":"内容記述","attribute_value_mlt":[{"subitem_description":"研究種目：若手研究;  研究期間：2019～2020;   課題番号：19K16876;   研究分野：薬理学   科研費の分科・細目：","subitem_description_type":"Other"}]},"item_8_description_37":{"attribute_name":"資源タイプ(WEKO2)","attribute_value_mlt":[{"subitem_description":"Research Paper","subitem_description_type":"Other"}]},"item_8_description_41":{"attribute_name":"フォーマット","attribute_value_mlt":[{"subitem_description":"application/pdf","subitem_description_type":"Other"}]},"item_8_publisher_14":{"attribute_name":"出版者 名前","attribute_value_mlt":[{"subitem_publisher":"近畿大学"}]},"item_8_text_10":{"attribute_name":"著者 役割","attribute_value_mlt":[{"subitem_text_value":"研究代表者"}]},"item_8_text_7":{"attribute_name":"著者(英)","attribute_value_mlt":[{"subitem_text_language":"en","subitem_text_value":"Hara, Yuta"}]},"item_8_text_8":{"attribute_name":"著者 所属","attribute_value_mlt":[{"subitem_text_value":"近畿大学薬学部; 助教"}]},"item_8_text_9":{"attribute_name":"著者所属(翻訳)","attribute_value_mlt":[{"subitem_text_value":"Kindai University"}]},"item_8_version_type_12":{"attribute_name":"版","attribute_value_mlt":[{"subitem_version_resource":"http://purl.org/coar/version/c_be7fb7dd8ff6fe43","subitem_version_type":"NA"}]},"item_creator":{"attribute_name":"著者","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"原, 雄大"},{"creatorName":"ハラ, ユウタ","creatorNameLang":"ja-Kana"}],"nameIdentifiers":[{"nameIdentifier":"43370","nameIdentifierScheme":"WEKO"},{"nameIdentifier":"20803779","nameIdentifierScheme":"NRID","nameIdentifierURI":"https://nrid.nii.ac.jp/ja/search/?kw=20803779"}]}]},"item_files":{"attribute_name":"ファイル情報","attribute_type":"file","attribute_value_mlt":[{"accessrole":"open_date","date":[{"dateType":"Available","dateValue":"2021-11-08"}],"displaytype":"detail","filename":"19K16876seika.pdf","filesize":[{"value":"366.0 kB"}],"format":"application/pdf","licensetype":"license_note","mimetype":"application/pdf","url":{"label":"19K16876seika.pdf","url":"https://kindai.repo.nii.ac.jp/record/22142/files/19K16876seika.pdf"},"version_id":"6013b086-ce45-470f-b194-8967e7ef1e2c"}]},"item_keyword":{"attribute_name":"キーワード","attribute_value_mlt":[{"subitem_subject":"ASCT2","subitem_subject_scheme":"Other"},{"subitem_subject":"KRAS","subitem_subject_scheme":"Other"},{"subitem_subject":"大腸癌","subitem_subject_scheme":"Other"},{"subitem_subject":"モノクローナル抗体","subitem_subject_scheme":"Other"}]},"item_language":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"jpn"}]},"item_resource_type":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"resourcetype":"research report","resourceuri":"http://purl.org/coar/resource_type/c_18ws"}]},"item_title":"新規抗ASCT2モノクローナル抗体を用いたKRAS遺伝子変異癌の治療戦略の開発","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"新規抗ASCT2モノクローナル抗体を用いたKRAS遺伝子変異癌の治療戦略の開発","subitem_title_language":"ja"},{"subitem_title":"Effects of novel anti-ASCT2 monoclonal antibody on human tumor harboring KRAS mutation","subitem_title_language":"en"}]},"item_type_id":"8","owner":"3","path":["4710"],"pubdate":{"attribute_name":"PubDate","attribute_value":"2021-11-08"},"publish_date":"2021-11-08","publish_status":"0","recid":"22142","relation_version_is_last":true,"title":["新規抗ASCT2モノクローナル抗体を用いたKRAS遺伝子変異癌の治療戦略の開発"],"weko_creator_id":"3","weko_shared_id":-1},"updated":"2023-08-13T06:15:05.208797+00:00"}